Hi Bubby,
Good point. However, the upside of this agreement outweighs potential development costs. These costs will most likely linked to developing further technologies for using these 'cells' (freezing - which RGS already has, or else). At first, RGS will do clinical studies of efficacy/safety.
Having said this, best news in months for RGS. As big as Kvax.
